logo-loader
viewBioasis Technologies Inc.

Full interview: Bioasis Technologies new CEO says favorable response from FDA on its xB3 therapy 'encouraging'

Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of breast cancer and brain metastases. Rathjen says the FDA's favorable feedback included a suggestion the company might consider the next steps of the drug development process towards entering Phase 1 trials.

Quick facts: Bioasis Technologies Inc.

Price: 0.1499 USD

OTCQB:BIOAF
Market: OTCQB
Market Cap: $9.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Spectra7 Microsystems CEO says Tencent partnership 'critical milestone' for...

Spectra7 Microsystems Inc (OTCMKTS:SEV) CEO Raouf Halim sat down with Proactive’s Steve Darling at the 12th annual LD Micro Conference in California. The San Jose, California-based semiconductor company services electronics manufacturers in virtual reality, augmented reality, mixed reality, data...

7 hours, 25 minutes ago

2 min read